pharma
Celgene Europe
Celgene Europe patent portfolio β 13 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- EU
- Programs
- 0
- Drugs
- 0
- Patents
- 13
Celgene Europe patents
13 pharmaceutical patents indexed for Celgene Europe. 0 expire within 24 months.
Celgene Europe has 13 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months β use filters for patent-cliff planning.
Patent portfolio
-
EP 3539539
TABLETTENFORMULIERUNGEN AUS (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLIN-1,3-DION
granted -
EP 3320902
VERFAHREN ZUR BEHANDLUNG VON ERKRANKUNGEN MIT ISOINDOLINVERBINDUNGEN
granted -
MX 2015008685
TREATMENT OF PSORIATIC ARTHRITIS USING APREMILAST.
granted -
AU 2012362562
Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
granted -
AU 2012308663
Formulations of cyclopropanecarboxylic acid {2-[1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware
granted -
AU 2012249536
Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
granted -
EP 2651400
ORALE RETARD-DARREICHUNGSFORMEN VON SCHWER LΓSLICHEN ARZNEIMITTELN UND IHRE VERWENDUNG
granted -
AU 2013203283
Processes for the preparation of (S)-1-(3-ethoxy-4-methoxyophenyl)-2-methanesulfonylethylamine
granted -
AU 2012205809
Phenethylsulfone isoindoline derivatives as inhibitors of PDE 4 and/or cytokines
granted -
EP 2555769
VERFAHREN ZUR BEHANDLUNG VON VIRALEN ATEMWEGSINFEKTIONEN
granted -
AU 2008353468
Solid forms comprising (+)-2- [1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
granted -
AU 2005269367
Isoindoline compounds and methods of their use
expired -
AU 2003224729
(+)-2-(1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL)-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF
expired
Frequently asked questions
How many patents does Celgene Europe have?
13 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Celgene Europe patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.